Fintel reports that on October 3, 2023, HC Wainwright & Co. reiterated coverage of Alx Oncology Holdings (NASDAQ:ALXO) with a Buy recommendation.
Analyst Price Forecast Suggests 99.85% Upside
As of August 31, 2023, the average one-year price target for Alx Oncology Holdings is 15.01. The forecasts range from a low of 5.05 to a high of $30.45. The average price target represents an increase of 99.85% from its latest reported closing price of 7.51.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alx Oncology Holdings is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -3.41.
What is the Fund Sentiment?
There are 218 funds or institutions reporting positions in Alx Oncology Holdings. This is a decrease of 26 owner(s) or 10.66% in the last quarter. Average portfolio weight of all funds dedicated to ALXO is 0.15%, an increase of 21.35%. Total shares owned by institutions decreased in the last three months by 5.83% to 35,201K shares. 
The put/call ratio of ALXO is 0.05, indicating a bullish outlook.
What are Other Shareholders Doing?
venBio Partners holds 9,700K shares representing 23.57% ownership of the company. No change in the last quarter.
Vivo Capital holds 4,220K shares representing 10.25% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 2,871K shares representing 6.98% ownership of the company. No change in the last quarter.
FBTAX - Fidelity Advisor Biotechnology Fund holds 1,350K shares representing 3.28% ownership of the company. In it's prior filing, the firm reported owning 1,206K shares, representing an increase of 10.72%. The firm increased its portfolio allocation in ALXO by 16.49% over the last quarter.
Redmile Group holds 1,283K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 587K shares, representing an increase of 54.26%. The firm increased its portfolio allocation in ALXO by 221.32% over the last quarter.
Alx Oncology Holdings Background Information
(This description is provided by the company.)
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
